Cargando…
Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery
SIMPLE SUMMARY: Nano-drug delivery systems serve as Trojan horses to carry therapeutic drugs as cargos and deliver them to target cells. The specificity of these delivery vehicles to a particular cell type can be improved if the surface of the vehicles is chemically modified in such a manner that th...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599460/ https://www.ncbi.nlm.nih.gov/pubmed/33019627 http://dx.doi.org/10.3390/cancers12102837 |
_version_ | 1783602879881281536 |
---|---|
author | Kou, Longfa Yao, Qing Zhang, Hailin Chu, Maoping Bhutia, Yangzom D. Chen, Ruijie Ganapathy, Vadivel |
author_facet | Kou, Longfa Yao, Qing Zhang, Hailin Chu, Maoping Bhutia, Yangzom D. Chen, Ruijie Ganapathy, Vadivel |
author_sort | Kou, Longfa |
collection | PubMed |
description | SIMPLE SUMMARY: Nano-drug delivery systems serve as Trojan horses to carry therapeutic drugs as cargos and deliver them to target cells. The specificity of these delivery vehicles to a particular cell type can be improved if the surface of the vehicles is chemically modified in such a manner that they are recognized and attracted to the target cell. This can be accomplished if the target cell selectively expresses a receptor or transporter and the surface of the drug-delivery vehicles is conjugated with the receptor agonist or the transporter substrate. In this review, we detail published literature on the successful exploitation of plasma membrane transporters for this purpose. In particular, this review emphasizes the delivery of chemotherapeutic drugs to cancer cells by targeting the nano-delivery systems specifically to certain transporters that are selectively upregulated in cancer cells. ABSTRACT: Nano-devices are recognized as increasingly attractive to deliver therapeutics to target cells. The specificity of this approach can be improved by modifying the surface of the delivery vehicles such that they are recognized by the target cells. In the past, cell-surface receptors were exploited for this purpose, but plasma membrane transporters also hold similar potential. Selective transporters are often highly expressed in biological barriers (e.g., intestinal barrier, blood–brain barrier, and blood–retinal barrier) in a site-specific manner, and play a key role in the vectorial transfer of nutrients. Similarly, selective transporters are also overexpressed in the plasma membrane of specific cell types under pathological states to meet the biological needs demanded by such conditions. Nano-drug delivery systems could be strategically modified to make them recognizable by these transporters to enhance the transfer of drugs across the biological barriers or to selectively expose specific cell types to therapeutic drugs. Here, we provide a comprehensive review and detailed evaluation of the recent advances in the field of transporter-targeted nano-drug delivery systems. We specifically focus on areas related to intestinal absorption, transfer across blood–brain barrier, tumor-cell selective targeting, ocular drug delivery, identification of the transporters appropriate for this purpose, and details of the rationale for the approach. |
format | Online Article Text |
id | pubmed-7599460 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75994602020-11-01 Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery Kou, Longfa Yao, Qing Zhang, Hailin Chu, Maoping Bhutia, Yangzom D. Chen, Ruijie Ganapathy, Vadivel Cancers (Basel) Review SIMPLE SUMMARY: Nano-drug delivery systems serve as Trojan horses to carry therapeutic drugs as cargos and deliver them to target cells. The specificity of these delivery vehicles to a particular cell type can be improved if the surface of the vehicles is chemically modified in such a manner that they are recognized and attracted to the target cell. This can be accomplished if the target cell selectively expresses a receptor or transporter and the surface of the drug-delivery vehicles is conjugated with the receptor agonist or the transporter substrate. In this review, we detail published literature on the successful exploitation of plasma membrane transporters for this purpose. In particular, this review emphasizes the delivery of chemotherapeutic drugs to cancer cells by targeting the nano-delivery systems specifically to certain transporters that are selectively upregulated in cancer cells. ABSTRACT: Nano-devices are recognized as increasingly attractive to deliver therapeutics to target cells. The specificity of this approach can be improved by modifying the surface of the delivery vehicles such that they are recognized by the target cells. In the past, cell-surface receptors were exploited for this purpose, but plasma membrane transporters also hold similar potential. Selective transporters are often highly expressed in biological barriers (e.g., intestinal barrier, blood–brain barrier, and blood–retinal barrier) in a site-specific manner, and play a key role in the vectorial transfer of nutrients. Similarly, selective transporters are also overexpressed in the plasma membrane of specific cell types under pathological states to meet the biological needs demanded by such conditions. Nano-drug delivery systems could be strategically modified to make them recognizable by these transporters to enhance the transfer of drugs across the biological barriers or to selectively expose specific cell types to therapeutic drugs. Here, we provide a comprehensive review and detailed evaluation of the recent advances in the field of transporter-targeted nano-drug delivery systems. We specifically focus on areas related to intestinal absorption, transfer across blood–brain barrier, tumor-cell selective targeting, ocular drug delivery, identification of the transporters appropriate for this purpose, and details of the rationale for the approach. MDPI 2020-10-01 /pmc/articles/PMC7599460/ /pubmed/33019627 http://dx.doi.org/10.3390/cancers12102837 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kou, Longfa Yao, Qing Zhang, Hailin Chu, Maoping Bhutia, Yangzom D. Chen, Ruijie Ganapathy, Vadivel Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery |
title | Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery |
title_full | Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery |
title_fullStr | Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery |
title_full_unstemmed | Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery |
title_short | Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery |
title_sort | transporter-targeted nano-sized vehicles for enhanced and site-specific drug delivery |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599460/ https://www.ncbi.nlm.nih.gov/pubmed/33019627 http://dx.doi.org/10.3390/cancers12102837 |
work_keys_str_mv | AT koulongfa transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery AT yaoqing transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery AT zhanghailin transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery AT chumaoping transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery AT bhutiayangzomd transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery AT chenruijie transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery AT ganapathyvadivel transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery |